Polypharmacology in drug Discovery // Drug Repurposing

Polypharmacology in drug Discovery

PolypharmacologyPolypharmacology is the rising innovative concept that focuses on the multi-target drugs. This field is separated from the classical “one drug, one target” philosophy.

This concept has been gaining a growing attention since the 1990s.

Polypharmacology is the treatment of diseases by modulating more than one target.

According to Andrew L. Hopkins from Department of Biological Chemistry and Drug Discovery, University of Dundee, UK, Polypharmacology can be defined as, “The modulation of several drug targets to achieve a desired therapeutic effect.”

Moreover, Aislyn and Ravi have presented that the “definition of polypharmacology encompasses both one drug binding to multiple targets and multiple drugs that bind to different targets within a network.”

It is an important area of integration between systems biology and drug discovery.

With the help of polypharmacology, researchers from different field can target complex diseases effectively such as the diseases with multiple pathogenic factors or diseases involving many genes.

Working on such drugs that have multiple targets could save a huge amount of money. It has been estimated that Research and Development efforts for a drug to move from the clinical trials to the market takes from 5 to 10 years and costs about US $1 billion. If the drug is for one target, it means the drug is effective for either one disease or a limited number of diseases but if the drug has a number of targets, it could effectively treat a number of diseases. So, the Pharmaceutical companies would be able to work against many diseases at the same cost and the consumers would be able to get single medicine for different (almost related) disorders. (It has been estimated that the value of many of the blockbuster drugs is about US 0 billion for generic manufacturers but the patents of those drugs will be expired by the next 3-5 years that would place the companies in a huge financial and research competition).

Examples of therapeutic polypharmacology (Credit: Curr Opin Drug Discov Devel.)Products of polypharmacology have not only increased therapeutic potency but also they are less likely to the development of resistance. They can also help in the prediction of side-effects by identifying multiple protein targets. (Unacceptable side-effects usually cause one-third of the potential therapeutic compounds to fail either in the clinical trials or in the market even after its launch.)

Further Reading:

Aislyn DW Boran and Ravi Iyengar, (2010). Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel, 13(3): 297–309. PMCID: PMC3068535

Durrant, J., Amaro, R., Xie, L., Urbaniak, M., Ferguson, M., Haapalainen, A., Chen, Z., Di Guilmi, A., Wunder, F., Bourne, P., & McCammon, J. (2010). A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology (1) DOI: 10.1371/journal.pcbi.1000648

You might also like

'Achilles Heel' Of Key HIV Replication Protein F

by QuQ

'Achilles Heel' Of Key HIV Replication Protein Found
Researchers at the University of Pittsburgh School of Medicine may have found an "Achilles heel" in a key HIV protein. In findings published online today in Chemistry and Biology, they showed that targeting this vulnerable spot could stop the virus from replicating, potentially thwarting HIV infection from progressing to full-blown AIDS.
Previous research demonstrated that a small HIV protein called Nef interacts with many other proteins in infected cells to help the virus multiply and hide from the immune system. The Pitt group developed a way to track Nef activity in high-throughput drug screening protocols by linking it to an enzyme called Hck, which is activated by Nef in HIV-infected cells, explained senior author Thomas E

Wiley Polypharmacology in Drug Discovery
Book (Wiley)

Cancer-Fighting Patch to Treat Mouth Cancer  — Drug Discovery & Development
Ohio State, through the Ohio State Innovation Foundation and the university's Drug Development Institute, and the University of Michigan licensed the intellectual property to the newly formed Sirona Therapeutics.